A Phase I, Open-Label, Dose-Seeking Study of AZD2171 [cediranib] Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin
Indications Colorectal cancer; Non-small cell lung cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

16 Mar 2010 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov record.
16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
10 Feb 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight